Description of Business and Summary of Significant Accounting Policies (Details) (USD $)
|
0 Months Ended |
3 Months Ended |
|
3 Months Ended |
1 Months Ended |
3 Months Ended |
0 Months Ended |
3 Months Ended |
|
3 Months Ended |
Jul. 12, 2012
|
Nov. 22, 2011
|
Jun. 30, 2014
Advisor
Customer
|
Jun. 30, 2013
|
Mar. 31, 2014
|
Jun. 30, 2014
Range $2.90 to $4.50 [Member]
|
Jun. 30, 2014
Range $6.00 to $11.70 [Member]
|
Jun. 30, 2014
Range $17.80 to $28.10 [Member]
|
Jun. 30, 2014
Range $34.20 to $89.52[Member]
|
Jun. 30, 2014
Range $2.90 to $89.52 [Member]
|
Aug. 02, 2014
Subsequent Event [Member]
|
Jun. 30, 2014
Stock Options [Member]
|
Jun. 30, 2013
Stock Options [Member]
|
Jul. 03, 2014
Stock Options [Member]
Subsequent Event [Member]
|
Jul. 03, 2014
Stock Options [Member]
Chief Executive Officer [Member]
Subsequent Event [Member]
|
Jun. 30, 2014
Restricted Stock Units (RSUs) [Member]
|
Jun. 30, 2014
Restricted Stock Units (RSUs) [Member]
Chief Executive Officer [Member]
|
Jul. 03, 2014
Restricted Stock Units (RSUs) [Member]
Chief Executive Officer [Member]
|
Jun. 30, 2014
Software [Member]
|
Jun. 30, 2014
Minimum [Member]
Software [Member]
|
Jun. 30, 2014
Minimum [Member]
Trade Names [Member]
|
Jun. 30, 2014
Minimum [Member]
Customer Relationships [Member]
|
Jun. 30, 2014
Minimum [Member]
Noncompete Agreements [Member]
|
Jun. 30, 2014
Maximum [Member]
Software [Member]
|
Jun. 30, 2014
Maximum [Member]
Trade Names [Member]
|
Jun. 30, 2014
Maximum [Member]
Customer Relationships [Member]
|
Jun. 30, 2014
Maximum [Member]
Noncompete Agreements [Member]
|
Jun. 30, 2014
Revenue [Member]
Quest Diagnostics [Member]
|
Jun. 30, 2014
Revenue [Member]
Cellnetix [Member]
|
Jun. 30, 2014
Revenue [Member]
Everyday Health [Member]
|
Jun. 30, 2013
Revenue [Member]
Everyday Health [Member]
|
Jun. 30, 2013
Revenue [Member]
Life Technologies [Member]
|
Jun. 30, 2014
Accounts Receivable [Member]
Quest Diagnostics [Member]
|
Jun. 30, 2013
Accounts Receivable [Member]
Life Technologies [Member]
|
Description of Business and Summary of Significant Accounting Policies [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
$ 1,248,000
|
$ 797,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities |
|
|
733,000
|
611,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Underwritten public offering of common stock (in shares) |
|
|
913,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Price |
|
|
$ 2.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of initial public offering |
|
|
1,827,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total underwriting discount and financing cost |
|
|
466,000
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from public offering before additional financing expenses |
|
|
1,641,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of clinical and scientific advisors |
|
|
75
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Concentration Risk [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Concentration risk (in hundredths) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.00%
|
23.00%
|
20.00%
|
7.00%
|
93.00%
|
95.00%
|
100.00%
|
Promissory Note [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business acquisition effective date |
Jul. 12,
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Promissory note assumed |
500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note receivable used as consideration for CollabRx acquisition |
|
300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate on promissory note (in hundredths) |
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Promissory note maturity date |
|
Nov. 15,
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of customers |
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment in convertible promissory note |
|
|
387,000
|
378,000
|
378,000
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued interest on note receivable |
|
|
87,000
|
78,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts Receivable - Allowance for Sales Returns and Doubtful Accounts [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reserves for potential credit losses |
|
|
0
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Warrant or Right [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants outstanding to purchase shares of common stock (in shares) |
|
|
27,405
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from sale of warrants |
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants (in dollars per share) |
|
|
$ 2.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment warrants expiration date range start |
|
|
Jun. 24,
2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment warrants expiration date range end |
|
|
Jun. 24,
2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value measurements [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash equivalents |
|
|
2,068,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Useful life |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10 years
|
3 years
|
3 years
|
3 years
|
3 years
|
10 years
|
10 years
|
10 years
|
10 years
|
|
|
|
|
|
|
|
Amortization of intangible assets |
|
|
52,000
|
52,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impairment of Long-Lived Assets [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impairment of long-lived assets |
|
|
0
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred financing costs amortization |
|
|
162,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total financing expenses, not including underwriters discount |
|
|
118,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-Based Compensation [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vesting period of equity awards |
|
|
4 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options expiry period |
|
|
10 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase price of shares to fair market value (in hundredths) |
|
|
85.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stock-based compensation expense related to stock options and restricted stock units |
|
|
94,000
|
84,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Valuation assumptions to estimate the fair value of options and ESPP [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expected life (years) |
|
|
|
|
|
|
|
|
|
|
|
|
6 years
|
6 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Volatility (in hundredths) |
|
|
|
|
|
|
|
|
|
|
|
|
151.70%
|
153.70%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Risk-free interest rate (in hundredths) |
|
|
|
|
|
|
|
|
|
|
|
|
1.68%
|
1.41%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividend yield (in hundredths) |
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock option and warrant activity [Roll Forward] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Beginning outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
371,759
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
11,668
|
|
122,400
|
100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercised (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expired (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
383,427
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending vested and expected to vest (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
383,148
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending exercisable (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
188,173
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Exercise Price [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Beginning outstanding (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 7.89
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 3.22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercised (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expired (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending outstanding (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 7.75
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending vested and expected to vest (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 7.75
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending exercisable (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 12.04
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Remaining Contractual Term [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
7 years 5 months 1 day
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending vested and expected to vest |
|
|
|
|
|
|
|
|
|
|
|
|
7 years 5 months 1 day
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending exercisable |
|
|
|
|
|
|
|
|
|
|
|
|
5 years 9 months 18 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate Intrinsic Value [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending vested and expected to vest |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending exercisable |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total unrecognized compensation cost related to outstanding options and warrants |
|
|
|
|
|
|
|
|
|
|
|
|
366,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Period of recognition of total unrecognized compensation cost related to options outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
2 years 9 months 18 days
|
|
|
|
1 year 1 month 6 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Shares [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, beginning of period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
129,050
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
137,025
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Released (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(37,250)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, end of period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
91,800
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Grant Date Fair Value [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, beginning of period (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2.77
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Released (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2.31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, end of period (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2.96
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total unrecognized compensation cost related to outstanding RSUs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 162,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested stock forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
138,203
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional shares to be granted in the future (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maximum annual number of shares authorized per participant (in shares) |
|
|
100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Range of Exercise Prices, Lower Range Limit (in dollars per share) |
|
|
|
|
|
|
$ 2.90
|
$ 6.00
|
$ 17.80
|
$ 34.20
|
$ 2.90
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Range of Exercise Prices, Upper Range Limit (in dollars per share) |
|
|
|
|
|
|
$ 4.50
|
$ 11.70
|
$ 28.10
|
$ 89.52
|
$ 89.52
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number Outstanding (in shares) |
|
|
|
|
|
|
282,997
|
48,690
|
39,244
|
12,496
|
383,427
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Remaining Contractual Term |
|
|
|
|
|
|
8 years 9 months 11 days
|
4 years 5 months 26 days
|
3 years 2 months 19 days
|
1 year 2 months 5 days
|
7 years 5 months 1 day
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Exercise Price (in dollars per share) |
|
|
|
|
|
|
$ 3.66
|
$ 11.12
|
$ 21.63
|
$ 43.65
|
$ 7.75
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number Exercisable (in shares) |
|
|
|
|
|
|
87,743
|
48,690
|
39,244
|
12,496
|
188,173
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Exercise Price (in dollars per share) |
|
|
|
|
|
|
$ 3.77
|
$ 11.12
|
$ 21.63
|
$ 43.65
|
$ 12.04
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|